fashion -WSS

fashion

author：explore 2025-08-23 18:38:09 - browse：8883

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Medicare Advantage enrollment hits roughly 33.4 million

explore

WSS

5 important ways Henrietta Lacks changed medical science

Mitch McConnell episode has important public health takeaway

Obamacare plans could cover weight loss drugs

Flagship Pioneering startup Sonata Therapeutics lays off 21

Scientists inch closer to single

Opioid cravings were reduced by anti

leisure time

fashion

hotspot

At least 13 dead in Texas as scorching temps continue

Infectious disease expert Jeanne Marrazzo assumes Fauci role

Trump demands the U.S. pay no more for drugs than other countries … again

Measles policy set amid Florida outbreak alarms vaccine proponents

Tori Bowie and the unacceptable rates of Black maternal death

Mega Millions pot grows to $1.25 billion after no winner

Tori Bowie and the unacceptable rates of Black maternal death

Ukraine seeks to reclaim its role as a hub for clinical trials

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Wikipedia

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Mega Millions pot grows to $1.25 billion after no winner

Ukraine seeks to reclaim its role as a hub for clinical trials

Scientists inch closer to single

Hospitals are piloting generative AI tools as regulators play catch

Medicare Advantage enrollment grows 7.1% to 33.4 million people

entertainment

focus

explore

leisure time